Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

Abstract excerpt

// Ethan Brill 1, * , Takuhei Yokoyama 1, * , Jayakumar Nair 1 , Minshu Yu 1 , Yeong-Ran Ahn 1 and Jung-Min Lee 1 1 Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA * These authors have contributed equally to this work Correspondence to: Jung-Min Lee, email: leej6@mail.nih.gov Keywords: cell cycle checkpoint kinase inhibitor; prexasertib; LY2606368; PARP...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to Ovarian cancer diagnosis and treatment
• Share to PARP inhibition in cancer therapy